|
Jul 30
|
Top FDA Official’s Surprise Departure Means More Uncertainty for Biotech
|
|
Jul 24
|
Sector Update: Health Care Stocks Softer in Afternoon Trading
|
|
Jul 24
|
Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs
|
|
Jul 24
|
Rocket lays off staff; Abivax capitalizes on immune drug data
|
|
Jul 18
|
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
|
|
Jul 17
|
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy
|
|
Jul 15
|
Rocket Pharmaceuticals Receives FDA IND Clearance for BAG3-DCM Gene Therapy RP-A701
|
|
Jul 10
|
Danon Disease Treatment Modality Market Analysis and Forecasts 2025-2035 | Next-Gen Sequencing Speeds Up Danon Disease Diagnosis and Treatment Pathways
|
|
Jul 1
|
RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance
|
|
Jul 1
|
Rocket Pharmaceuticals receives FDA clearance of RP-A701
|
|
Jun 30
|
Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy
|
|
Jun 20
|
Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street.
|
|
May 9
|
RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus
|
|
May 8
|
Rocket Pharmaceuticals: Q1 Earnings Snapshot
|
|
May 8
|
Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress
|
|
Mar 2
|
When Will Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Turn A Profit?
|
|
Feb 28
|
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus
|
|
Feb 27
|
Rocket Pharmaceuticals: Q4 Earnings Snapshot
|
|
Feb 27
|
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
|
|
Jan 2
|
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
|